Baird Remains Bullish as Market Reacts to Cempra's (CEMP) 2nd Phase 3 Study of Solithromycin

Baird reiterated an Outperform rating and $38.00 price target on Cempra, Inc. (NASDAQ: CEMP) following the company's second Phase 3 study of solithromycin.

Analyst Brian Skorney commented, "While the market is clearly reacting to potential signals about safety, we believe that the second Phase 3 study of solithromycin is completely consistent with the first Phase 3 outcome, supporting a US approval and European for community-acquired bacterial pneumonia (CABP)."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $19.29 yesterday.

You May Also Be Interested In

• Baird Reiterates Outperform Rating on Tesla (TSLA)
• Public Storage (PSA) PT Raised to $338 at Truist Securities
• ACM Research, Inc. (ACMR) PT Raised to $130 at Morgan Stanley